News
astrazeneca-sign

AZ posts solid Q1 results as Alexion merger looms

AstraZeneca's not-for-profit coronavirus vaccine has bit into margins in Q1, although revenues were ahead of expectations as the company heads towards completion of its $39bn acquisition of

Debates & Insights

News

Press Releases

Newsletters and Deep Dive
digital magazine

Views & Analysis

Webinars

Podcasts

Video

White Papers

Event

Partner Content

Debates & Insight